微生物来源的α-葡萄糖苷酶抑制剂国内外生产情况及市场分析

The Abroad and Home Production Situation and Market Analysis of α-Glucosidase Inhibitors from Microorganisms

由于生活水平的提高,糖尿病的发病率日益上升,其已成为人类健康的三大杀手之一,为其寻求高效的治疗药物,已成为当今的主流话题。自从发现阿卡波糖,α-葡萄糖苷酶抑制剂作为一种新型的降糖药物出现在人类面前,并且在治疗糖尿病,尤其是针对2型糖尿病有独特的优势。本文通过对微生物来源的α-葡萄糖苷酶抑制剂类药物的调研,了解阿卡波糖、伏格列波糖和米格列醇3种α-葡萄糖苷酶抑制剂当今市场情况,运用SWOT分析方法预测其市场前景,期望能为相关企业生产经营方向的选择、医院临床用药及政府指导性定价等提供导向。

With the increase of our living level, the incidence of diabetes was also rising day by day. Now it had become one of the top three killers to human health. Seeking medicine of high efficiency had become a main current topic. Since the find of arcabose, the α-glucosidase inhibitor appeared as a new kind of hypoglycemic drugs in front of human beings. Furthermore, it had an unique advantage in curing diabetes, especially the type 2 diabetes. Through the research of the production situation of α-glucosidase inhibitors from Microorganisms, the current situations of the 3 kinds of α-glucosidase inhibitors （arcabose, voglibose, miglitol） in the market were understood, and its market prospect were predicted by the SWOT analyzing method. It was expected that there will be some guide for the relevant enterprises, the clinical drug application of hospitals and price fix of government departments.